// App-Quantinova.ai

e15685 : A haploid genetic screen identifies the key determinant of response to novel combination therapy with gemcitabine and entinostat in pancreatic cancer.

Researchers

Presenter

  • Yuk Ting Ma

Principal Investigators

  • Sarah Leonard

  • Naheema Gordon

  • Jennifer Anderton

  • David Huen

  • Ciaran Woodman

  • Daniel H. Palmer

Medical Centers

  • University of Birmingham, Birmingham, United Kingdom

  • University of Wolverhampton, Wolverhampton, United Kingdom

  • University of Liverpool Cancer Research UK Centre, Liverpool, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Obstetrics/Gynecology

Disease

  • Pancreatic cancer

  • Twin-reversed arterial perfusion

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Entinostat

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved